Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories is an integrated pharmaceutical company operating globally, with a presence in North America, Europe, India, Russia, and other regions. Its operations are divided into three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products, both branded and generic, including biologics. The PSAI segment produces active pharmaceutical ingredients (APIs) and intermediates, and offers contract research services. The Others segment focuses on developing therapies for oncology and inflammation, as well as differentiated formulations. The company's products cover a wide range of therapeutic categories such as gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, urology, and pain management.

Dr. Reddy's Laboratories is listed on the New York Stock Exchange (NYSE) under the ticker symbol RDY. Its shares are traded in US Dollars (USD). The company is headquartered in Hyderabad, India, and its primary listing is on the NYSE, making it accessible to international investors. The use of USD as the trading currency facilitates investment from US and global markets.

Dr. Reddy's Laboratories operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is primarily involved in the development, manufacturing, and marketing of pharmaceutical products, with a focus on generic drugs and specialty pharmaceuticals. As a generic drug manufacturer, it produces medications that are therapeutically equivalent to branded drugs, often at lower costs. The specialty aspect indicates that it also engages in more complex or niche therapeutic areas, such as biologics and differentiated formulations.

Dr. Reddy's Laboratories is headquartered in Hyderabad, India, and was incorporated in 1984. The company serves a global market, with a strong presence in North America, Europe, India, Russia, and other regions. Its operations are structured to cater to diverse healthcare needs worldwide, offering products across various therapeutic categories including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, urology, and pain management. The company's global reach allows it to distribute both generic and branded pharmaceuticals, as well as active pharmaceutical ingredients, to a wide range of customers.

Dr. Reddy's Laboratories generates revenue through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment is the main revenue driver, selling prescription and over-the-counter finished pharmaceutical products, both branded and generic, as well as biologics. The PSAI segment contributes by manufacturing and selling active pharmaceutical ingredients (APIs) and intermediates to other pharmaceutical companies, and by providing contract research services. The Others segment includes the development of therapies for oncology and inflammation, and the research and commercialization of differentiated formulations. This diversified business model allows the company to capture value across the pharmaceutical value chain, from raw materials to finished products.